We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 11.50 | 0.70% | 1,651.00 | 1,651.00 | 1,652.00 | 1,656.00 | 1,637.00 | 1,650.50 | 4,661,376 | 16:35:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.80 | 68.01B |
From Apr 2019 to Apr 2024
TIDMGSK
RNS Number : 7867C
GlaxoSmithKline PLC
19 April 2017
GlaxoSmithKline plc (the 'Company')
Transaction notification
Hot Features
Premium
1. Details of PDMR/person closely associated with them
('PCA')
=== ===========================================================================
a) Name Ms E Walmsley
=== ======================== =================================================
b) Position/status Chief Executive Officer
=== ======================== =================================================
c) Initial notification/ Initial notification
amendment
=== ======================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===========================================================================
a) Name GlaxoSmithKline plc
=== ======================== =================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's Deferred
Investment Award Programme.
=== ======================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP16.39 575.028
---------- ----------
=== ======================== =================================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== =================================================
e) Date of the transaction 2017-04-13
=== ======================== =================================================
f) Place of the n/a
transaction
=== ======================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===========================================================================
a) Name Mr R G Connor
=== ======================== =================================================
b) Position/status President, Global Manufacturing & Supply
=== ======================== =================================================
c) Initial notification/ Initial notification
amendment
=== ======================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===========================================================================
a) Name GlaxoSmithKline plc
=== ======================== =================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 13 April 2017,
on Ordinary Shares held in the Company's
Deferred Investment Award Programme.
=== ======================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP16.39 230.011
---------- ----------
=== ======================== =================================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== =================================================
e) Date of the transaction 2017-04-13
=== ======================== =================================================
f) Place of the n/a
transaction
=== ======================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===========================================================================
a) Name Mr S A Hussain
=== ======================== =================================================
b) Position/status President, Global Pharmaceuticals
=== ======================== =================================================
c) Initial notification/ Initial notification
amendment
=== ======================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===========================================================================
a) Name GlaxoSmithKline plc
=== ======================== =================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's Deferred
Investment Award Programme.
=== ======================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP16.39 287.514
---------- ----------
=== ======================== =================================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== =================================================
e) Date of the transaction 2017-04-13
=== ======================== =================================================
f) Place of the n/a
transaction
=== ======================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr B McNamara
=== ======================== ================================================
b) Position/status CEO, GSK Consumer Healthcare
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of GlaxoSmithKline plc American Depositary
the financial Shares ('ADSs')
instrument ISIN: US37733W1053
=== ======================== ================================================
b) Nature of the Increase in notional interest in ADSs following
transaction the re-investment of dividends paid to
shareholders on 13 April 2017 on ADSs held
in the Company's Deferred Investment Award
Programme.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
$41.8150 359.648
--------- ----------
=== ======================== ================================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ================================================
e) Date of the transaction 2017-04-13
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===========================================================================
a) Name Mr D S Redfern
=== ======================== =================================================
b) Position/status Chief Strategy Officer
=== ======================== =================================================
c) Initial notification/ Initial notification
amendment
=== ======================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===========================================================================
a) Name GlaxoSmithKline plc
=== ======================== =================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's Deferred
Investment Award Programme.
=== ======================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP16.39 230.011
---------- ----------
=== ======================== =================================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== =================================================
e) Date of the transaction 2017-04-13
=== ======================== =================================================
f) Place of the n/a
transaction
=== ======================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Ms C Thomas
=== ======================== ================================================
b) Position/status Senior Vice President, HR
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's Deferred
Investment Award Programme.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP16.39 230.011
---------- ----------
=== ======================== ================================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ================================================
e) Date of the transaction 2017-04-13
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Dr P J T Vallance
=== ======================== ================================================
b) Position/status President, R&D
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's Deferred
Investment Award Programme.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP16.39 287.514
---------- ----------
=== ======================== ================================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ================================================
e) Date of the transaction 2017-04-13
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHQKLFFDZFXBBQ
(END) Dow Jones Newswires
April 19, 2017 12:38 ET (16:38 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
